Gallbladder cancer

What it is

Gallbladder cancer is a rare cancer of the gallbladder, and adenocarcinoma accounts for most cases. The single most important practical fact is that it is often found late because early disease may cause no symptoms or symptoms that look like common gallstone problems. The gallbladder is a small organ under the liver that stores bile. Cancer starts in its lining and can grow into the liver, nearby lymph nodes, bile ducts, or more distant organs.

Gallbladder cancer is uncommon overall, but it is the most common cancer of the biliary tract in many regions. Rates vary widely by geography and ethnicity, with higher burdens reported in parts of South America and Asia, including northern India. In India, clinicians are especially alert to this disease in patients from high-incidence belts such as the Gangetic plain.

Most tumours are adenocarcinomas. Less common types include squamous, adenosquamous, neuroendocrine, and other rare histologies.

Main point	Detail
Usual cell type	Adenocarcinoma
Common presentation	Abdominal pain, jaundice, weight loss, or an incidental finding after gallbladder surgery
Why it is serious	It often spreads locally before diagnosis
Important risk factor	Gallstones are strongly associated, though most people with gallstones never develop cancer

How it works

Gallbladder cancer usually develops after long-term irritation and inflammation of the gallbladder lining. Gallstones are the best-known associated factor. Chronic inflammation may lead to changes in the lining, then dysplasia, and eventually invasive cancer in some patients. Other recognised risk factors include older age, female sex, large gallstones, porcelain gallbladder, gallbladder polyps of concern, certain congenital pancreaticobiliary junction abnormalities, chronic infections such as Salmonella typhi carriage, obesity, and some environmental exposures.

The cancer can spread in several ways:

1. Direct extension into the liver because the gallbladder lies against the liver.
2. Lymphatic spread to nearby lymph nodes.
3. Peritoneal spread within the abdomen.
4. Blood-borne spread to distant organs in advanced disease.

This pattern matters because even a small tumour can be difficult to cure if it has already invaded the liver bed or regional nodes.

Evidence and uses

For a cancer entry, this section focuses on standard treatment uses and what evidence supports them. The main treatment depends on the stage.

Localised disease

If the cancer is confined to the inner layers of the gallbladder, surgery offers the best chance of cure. Very early tumours may be adequately treated by simple cholecystectomy if they are limited to the mucosa. For more invasive tumours, surgeons often recommend extended or radical cholecystectomy, which may include removal of part of the liver next to the gallbladder and regional lymph nodes.

Incidentally detected gallbladder cancer

Some cases are found only after a gallbladder is removed for presumed benign disease such as gallstones. This is called incidentally detected gallbladder cancer. Management then depends on the pathology stage, margin status, and imaging findings. For selected patients with tumours beyond the earliest stage, re-resection of the liver bed and lymph nodes can improve staging and may improve outcomes.

Advanced or metastatic disease

If the cancer cannot be removed completely, treatment may include systemic therapy, biliary drainage for jaundice, radiation in selected cases, and supportive care. Modern treatment of advanced biliary tract cancers often uses combination chemotherapy, and some patients may also be tested for molecular targets or immunotherapy markers. However, gallbladder cancer is less common than other biliary cancers, so some evidence comes from broader biliary tract cancer studies rather than gallbladder-only trials.

Screening

There is no established population screening test for gallbladder cancer. Imaging or specialist follow-up may be considered in people with specific high-risk findings, but routine screening of the general population is not standard.

Diagnosis / how it's measured

Diagnosis usually starts with imaging and is confirmed by pathology.

Test or step	What it helps show
Ultrasound	Gallbladder mass, wall thickening, stones, biliary dilation
Contrast CT or MRI/MRCP	Local spread, liver invasion, lymph nodes, operability
Blood tests	Liver function, bilirubin, overall fitness for treatment
Tumour markers such as CA 19-9 or CEA	May support assessment, but are not diagnostic on their own
Pathology after biopsy or surgery	Confirms cancer type, grade, margins, and stage

Doctors stage gallbladder cancer using the TNM system, which describes tumour depth and spread to nodes or distant organs. Stage is the main guide to treatment and prognosis.

A few points are important for patients and families:

• Symptoms are often nonspecific. Right upper abdominal pain, nausea, poor appetite, jaundice, itching, fever, and weight loss can overlap with gallstones or infection.
• Incidental diagnosis is common. A cancer may be found only after routine cholecystectomy.
• Liquid biopsy is not standard care yet. Research is active, but blood-based tumour DNA tests for gallbladder cancer remain investigational and are not a replacement for imaging and tissue diagnosis.

When to see a clinician

See a clinician promptly if there is persistent right upper abdominal pain, jaundice, pale stools, dark urine, unexplained weight loss, loss of appetite, or a gallbladder mass or suspicious polyp on imaging. Urgent evaluation is especially important if jaundice is new, because it can signal bile duct blockage or advanced disease.

People who have had gallbladder surgery should ask for the pathology report if cancer was found incidentally. In that situation, review by a hepatobiliary surgeon or gastrointestinal cancer team is important because further imaging or another operation may be considered depending on the stage.

In India, referral to a centre with hepatobiliary surgery, GI oncology, pathology review, and cross-sectional imaging can be useful because treatment decisions often depend on precise staging and surgical expertise.

Limitations and open questions

Gallbladder cancer remains difficult to study because it is relatively rare in many countries, but common in certain regions. That means some treatment recommendations are based on retrospective studies, institutional series, or trials that combine several biliary tract cancers rather than gallbladder cancer alone.

Several areas are still evolving:

• Best management of incidental cancers after cholecystectomy, especially for borderline stages.
• Role of molecular testing and which targeted or immune treatments help specific subgroups.
• Use of liquid biopsy, which is promising but not yet routine.
• Prevention in high-risk populations, including how to identify which patients with gallstones, polyps, or chronic inflammation need closer follow-up.

Evidence is stronger for surgery in early-stage disease than for many newer tests. Because symptoms can mimic benign gallbladder disease, diagnosis is often delayed. Anyone with suspected gallbladder cancer should discuss staging, pathology review, and treatment options with a specialist team rather than relying on symptoms alone.